Clinical trial
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
NCT05627960
Study timeline
Study start (actual)2022-02-14Date precision: day
Registry last updated2022-11-28
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Triple Negative Breast Cancerunresolved
Hormone-Resistant Breast Cancerunresolved
Non Small Cell Lung Cancerunresolved
Mesotheliomaunresolved
Interventions
AG-01 CompoundDRUG
Sponsors & collaborators
A&G Pharmaceutical Inc.lead sponsor
University of Maryland Greenebaum Cancer Centercollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05627960 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.